Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Cancer immunoediting: from immunosurveillance to tumor escape.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD.

Nat Immunol. 2002 Nov;3(11):991-8. Review.

PMID:
12407406
2.

Interferon-gamma and cancer immunoediting.

Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD.

Immunol Res. 2005;32(1-3):231-45. Review.

PMID:
16106075
3.

The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.

Algarra I, García-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F.

Cancer Immunol Immunother. 2004 Oct;53(10):904-10. Epub 2004 Apr 7. Review.

PMID:
15069585
4.

The immune system--is it relevant to cancer development, progression and treatment?

Prestwich RJ, Errington F, Hatfield P, Merrick AE, Ilett EJ, Selby PJ, Melcher AA.

Clin Oncol (R Coll Radiol). 2008 Mar;20(2):101-12. Epub 2007 Nov 26. Review.

PMID:
18037277
5.

Tumor-host immune interactions and dendritic cell dysfunction.

Yang L, Carbone DP.

Adv Cancer Res. 2004;92:13-27. Review.

PMID:
15530555
6.

The critical role of type-1 innate and acquired immunity in tumor immunotherapy.

Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, Nishimura T.

Cancer Sci. 2004 Sep;95(9):697-703. Review.

7.

[The relationship between immunological defence and the development of tumours].

Leone G.

Arch Sci Med (Torino). 1973 Oct-Dec;130(4):273-82. Review. Italian.

PMID:
17343168
8.

Cancer immunoediting and "spontaneous" tumor regression.

Sengupta N, MacFie TS, MacDonald TT, Pennington D, Silver AR.

Pathol Res Pract. 2010 Jan 15;206(1):1-8. doi: 10.1016/j.prp.2009.10.001. Epub 2009 Nov 27. Review.

PMID:
19945228
9.

MHC class I antigens, immune surveillance, and tumor immune escape.

Garcia-Lora A, Algarra I, Garrido F.

J Cell Physiol. 2003 Jun;195(3):346-55. Review.

PMID:
12704644
10.
11.

The immunobiology of cancer immunosurveillance and immunoediting.

Dunn GP, Old LJ, Schreiber RD.

Immunity. 2004 Aug;21(2):137-48. Review.

12.

Human leukocyte antigen-G and cancer immunoediting.

Urosevic M, Dummer R.

Cancer Res. 2008 Feb 1;68(3):627-30. doi: 10.1158/0008-5472.CAN-07-2704. Review.

13.

The three Es of cancer immunoediting.

Dunn GP, Old LJ, Schreiber RD.

Annu Rev Immunol. 2004;22:329-60. Review.

PMID:
15032581
14.

Immune selection in murine tumors. Ph.d thesis.

Svane IM, Engel AM.

APMIS Suppl. 2003;(106):1-46.

PMID:
12739251
15.

Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells.

Corthay A, Lundin KU, Lorvik KB, Hofgaard PO, Bogen B.

Cancer Res. 2009 Jul 15;69(14):5901-7. doi: 10.1158/0008-5472.CAN-08-4816. Epub 2009 Jun 30.

16.

Natural immunity to cancer in humans.

Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J.

Curr Opin Immunol. 2010 Apr;22(2):215-22. doi: 10.1016/j.coi.2010.02.006. Epub 2010 Mar 6. Review.

PMID:
20207124
17.

Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines.

Dupont B.

Immunol Rev. 2002 Oct;188:5-8. Review. No abstract available.

PMID:
12445276
18.

Immunoepigenetics: the unseen side of cancer immunoediting.

Germenis AE, Karanikas V.

Immunol Cell Biol. 2007 Jan;85(1):55-9. Epub 2006 Nov 28. Review.

PMID:
17130900
19.
20.

Commentary: Immune escape versus tumor tolerance: how do tumors evade immune surveillance?

Salih HR, Nüssler V.

Eur J Med Res. 2001 Aug 27;6(8):323-32. Review.

PMID:
11549514

Supplemental Content

Support Center